We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intra-arterial Chemotherapy for Children With Retinoblastoma

This study is currently recruiting participants.
Verified October 2016 by Michael Weintraub, Hadassah Medical Organization
Sponsor:
ClinicalTrials.gov Identifier:
NCT00906113
First Posted: May 21, 2009
Last Update Posted: October 4, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Michael Weintraub, Hadassah Medical Organization
  Purpose

Retinoblastoma is a cancer of the eye that occurs exclusively in children. The treatment for retinoblastoma may include surgery, chemotherapy, radiation and local treatments to the eye such as freezing (cryotherapy) and local radiation (brachytherapy). In some cases, a child with retinoblastoma will have active cancer in a single remaining eye with useful vision. In such cases, it is sometimes necessary to remove this eye. In such cases, the injection of chemotherapy directly into the artery that supplies the eye and the tumor may lead to regression of the tumor without the need to remove the eye.

This form of treatment was pioneered by a group in New York (Abramson et al). In this study the investigators will assess the efficacy and safety of the technique in a group of children with retinoblastoma.


Condition Intervention Phase
Retinoblastoma Drug: Intra-arterial injection of melphalan Drug: Injection of melphalan into the ophthalmic artery Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1-2 Study of Injection of Melphalan Into the Ophthalmic Artery in Children With Retinoblastoma

Resource links provided by NLM:


Further study details as provided by Michael Weintraub, Hadassah Medical Organization:

Primary Outcome Measures:
  • Salvage of eye and vision [ Time Frame: Three years from intervention ]

Estimated Enrollment: 10
Study Start Date: June 2011
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intra-arterial melphalan
The patients will be treated by injection of chemotherapy (melphalan) into the ophthalmic artery of an eye affected by retinoblastoma
Drug: Intra-arterial injection of melphalan
Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
Drug: Injection of melphalan into the ophthalmic artery
Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Months to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children with retinoblastoma in a single remaining eye with useful vision

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00906113


Contacts
Contact: Michael Weintraub, MD 972-2-6777408 michaelw@hadassah.org.il
Contact: Jacob Pe'er, MD 972-26778431

Locations
Israel
Hadassah University Hospital Recruiting
Jerusalem, Israel, 91120
Contact: Michael Weintraub, MD       michaelw@hadassah.org.il   
Principal Investigator: Michael Weintraub, MD         
Sponsors and Collaborators
Hadassah Medical Organization
  More Information

Responsible Party: Michael Weintraub, DIrector, Pediatric Hematology Oncology, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00906113     History of Changes
Other Study ID Numbers: 0058-09-HMO
First Submitted: May 19, 2009
First Posted: May 21, 2009
Last Update Posted: October 4, 2016
Last Verified: October 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Keywords provided by Michael Weintraub, Hadassah Medical Organization:
Retinoblastoma

Additional relevant MeSH terms:
Retinoblastoma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Retinal Neoplasms
Eye Neoplasms
Neoplasms by Site
Eye Diseases
Retinal Diseases
Melphalan
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs